(Q38011256)

26 August 2017

Drug discovery for a new generation of covalent drugs (English)

1 reference

26 August 2017

1 reference

Amit S Kalgutkar

1

1 reference

PubMed ID

22607458

26 August 2017

Deepak K Dalvie

series ordinal

2

1 reference

PubMed ID

22607458

26 August 2017

language of work or name

English

0 references

publication date

19 May 2012

1 reference

Expert Opinion on Drug Discovery

26 August 2017

1 reference

26 August 2017

7

1 reference

26 August 2017

561-581

1 reference

26 August 2017

7

1 reference

Covalent modifiers: an orthogonal approach to drug design

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

The resurgence of covalent drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Irreversible inhibitors of serine, cysteine, and threonine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Pharmacogenetics of drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Animal models of idiosyncratic drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Brief history of chemical carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Mechanistic basis of enzyme-targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Application of the Hard and Soft, Acids and Bases (HSAB) theory to toxicant--target interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Application of structure-activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity of alpha,beta-unsaturated aldehydes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Prediction of Michael-Type Acceptor Reactivity toward Glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Targeted covalent drugs of the kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Studies on the mechanism of the formation of the penicillin antigen. III. The N-(D-alpha-benzylpenicilloyl) group as an antigenic determinant responsible for hypersensitivity to penicillin G

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Immune-mediated adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structure-guided inhibitor design for human FAAH by interspecies active site conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Quantitative reactivity profiling predicts functional cysteines in proteomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Development of nitrile-based peptidic inhibitors of cysteine cathepsins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

The pH dependencies of individual rate constants in papain-catalyzed reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Novel and potent cyclic cyanamide-based cathepsin K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

The consequences of lysosomotropism on the design of selective cathepsin K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Identification of a potent and selective non-basic cathepsin K inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structure-activity relationships for thiol reactivity and rat or human hepatocyte toxicity induced by substituted p-benzoquinone compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Chemical reactivity of methoxy 4-o-aryl quinolines: identification of glutathione displacement products in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Intrinsic electrophilicity of the 4-methylsulfonyl-2-pyridone scaffold in glucokinase activators: role of glutathione-S-transferases and in vivo quantitation of a glutathione conjugate in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Non-enzymatic glutathione reactivity and in vitro toxicity: a non-animal approach to skin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structure-activity relationships for reactivity of carbonyl-containing compounds with glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

A simple in vitro assay for assessing the reactivity of nitrile containing compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structure of the C-terminal domain of human La protein reveals a novel RNA recognition motif coupled to a helical nuclear retention element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Reversible covalent binding of neratinib to human serum albumin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Characterization of HKI-272 covalent binding to human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Activity-based protein profiling: from enzyme chemistry to proteomic chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)--a general method for mapping sites of probe modification in proteomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Discovering potent and selective reversible inhibitors of enzymes in complex proteomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Profiling enzyme activities in vivo using click chemistry methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Examination of Michael addition reactivity towards glutathione by transition-state calculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Redox ranking of inducers of a cancer-protective enzyme via the energy of their highest occupied molecular orbital

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

The role of metabolic activation in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Concordance of the toxicity of pharmaceuticals in humans and in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.688744

10.1517/17460441.2012.688744

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22607458